AIC. Dynavax.
Dynavax is developing Amb a 1 immunostimulatory oligodeoxynucleotide-conjugate (AIC) as a potential immunotherapy for ragweed-induced seasonal allergy. By May 2001, phase II/III trials were underway in Canada and the US, and by March 2002, phase II trials were underway in France. In October 2002, Dynavax expected to commence a phase III trial in 2003.
Bohle
Barbara
B
Department of Pathophysiology, Division of Immunopathology, University of Vienna, AKH-EBO 3Q, Wahringer Gurtel 18-20, 1090 Vienna, Austria. barbara.bohle@akh-wien.ac.at
D000485:Allergens / Q000494:pharmacology / Q000627:therapeutic use; D031164:Ambrosia; D000818:Animals; D018926:Anti-Allergic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D052179:Antigens, Plant; D006801:Humans; D010940:Plant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D006255:Rhinitis, Allergic, Seasonal / Q000517:prevention & control*; D013678:Technology, Pharmaceutical / Q000331:legislation & jurisprudence / Q000379:methods*
D000485:Allergens; C026967:Amb a I protein, Ambrosia artemisiifolia; D018926:Anti-Allergic Agents; D052179:Antigens, Plant; D010940:Plant Proteins